ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 846

Preferential Binding to Elk-1 by SLE-Associated IL10 Risk Allele up-Regulates IL10 Expression

Daisuke Sakurai1, Jian Zhao1, Yun Deng1, Jennifer A. Kelly2, Kathy Moser Sivils2, Kenneth M. Kaufman3, Elizabeth E. Brown on behalf of PROFILE4, Marta E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network5, John B. Harley6, Sang-Cheol Bae7, Chaim O. Jacob8, Timothy J. Vyse9, Timothy B. Niewold10, Patrick M. Gaffney11, Judith A. James2, Robert P. Kimberly12, Gary S. Gilkeson13, Diane L. Kamen14, Carl D. Langefeld15, Deh-Ming Chang16, Yeong Wook Song17, Weiling Chen1, Jennifer M. Grossman1, Bevra H. Hahn18 and Betty P. Tsao1, 1Division of Rheumatology, Department of Medicine, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 31Center for Autoimmune Genomics and Etiology and Rheumatology Division, Cincinnati Children’s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 4University of Alabama at Birmingham, Birmingham, AL, 5Arthritis and Clinical Immunology, Centro de Genómica e Investigación Oncológica Pfizer-Universidad de Granada-Junta de Andalucía (GENYO), Granada, Spain and Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, 7Hanyang University Hospital for Rheumatic Disease, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, 8Department of Medicine,, Keck School of Medicine, University of Southern California, Los Angeles, CA, 9Divisions of Genetics and Molecular Medicine and Immunology,, King's College London, London, United Kingdom, 10Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, 11Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 13Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, 14Department of Medicine, Arthritis & Clinical Immunology Program, Oklahoma Medical Research Foundation, Charleston, SC, 15Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 16Headquarter, National Defense Medical Center, Taipei, 17Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, 18Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Elk-1, interleukins-10, polymorphism and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The established association between IL10 and multiple autoimmune diseases including SLE and elevated levels of IL-10 in SLE patients correlating with disease activity led us to fine-map theIL10 family locus (IL10-IL19-IL20-IL24) to evaluate SLE-associated SNPs for their potential functions in multiple ancestries.

Methods:

We genotyped 19 tag SNPs of the 154 kb IL10 family locus in 15533 subjects including European Americans (EA, 3820 cases vs 3412 controls), African Americans (1670 vs 1904), Asians (1252 vs 1249) and Hispanics (1445 vs 781), and imputed an additional 109 SNPs in EA. Each SNP was assessed for association with SLE, and haplotype-based conditional testing was conducted to distinguish independent signals. Transcript and protein levels of IL-10 were measured by real-time PCR and ELISA. EMSA was performed using nuclear lysates of SLE PBLs to assess differential binding to SLE-associated SNP alleles that might regulate IL-10 expression. Elk-1 activation was detected by Western blot, and co-localization of IL-10 and phospho-Elk-1 by flow cytometry.  

Results:

Among 19 genotyped SNPs, the 3’UTR downstream SNP of IL10, rs3024505, exhibited the strongest independent association with SLE susceptibility in EA only (P = 2.67×10-8, OR [95%CI] =1.30 [1.19-1.43]).   Lower allelic frequencies of this SNP and lack of other association signals in non-EA led us to focus on EA for imputation, showing association with SLE of 3 additional SNPs: rs3122605 (10kb 5′ upstream), rs3024493 (intron3) and rs3024495 (intron4) tagged by rs3024505 (r2>0.91). SLE patients carrying risk-alleles of these 4 SNPs had higher IL10 expression at mRNA (P=3.8 x 10-6) and protein level (P=4.2 x 10-5) than those carrying non-risk alleles. Only the risk allele of rs3122605 exhibited binding to nuclear extracts from SLE PBLs using EMSA. This risk allele was predicted to preferentially bind to transcription factor Elk-1, and was validated by supershift in the presence of ELK-1 antibodies, suggesting it is the likely causal variant. Upon activation, cytoplasmic Elk-1 is known to be phosphorylated and translocated into the nucleus inducing transcription. Phospho-Elk-1 was detected in nuclear extracts from SLE but not normal PBMCs, and appeared higher in patients with increasing SLEDAI scores (Figure). Co-expression of phospho-Elk-1 and IL-10 in PBLs was elevated in SLE than controls (P = 0.005) and active than inactive patients (P < 0.05).

Conclusion:

We identified GWAS level association (P<5×10-8) of 4 IL10 SNPs with SLE in EA. The risk allele of 5′ upstream rs3122605 preferentially binding to ELK-1 was associated with elevated IL10 levels. Nuclear localization of activated phospho-Elk-1 was elevated in SLE PBLs that also expressed IL-10, especially during active disease. Taken together, the SLE-associated rs3122605 C allele conferred SLE risk by upregulating ELK-1-mediated IL-10 expression.


Disclosure:

D. Sakurai,
None;

J. Zhao,
None;

Y. Deng,
None;

J. A. Kelly,
None;

K. Moser Sivils,
None;

K. M. Kaufman,
None;

E. E. Brown on behalf of PROFILE,
None;

M. E. Alarcón-Riquelme on behalf of BIOLUPUS and GENLES network,
None;

J. B. Harley,
None;

S. C. Bae,
None;

C. O. Jacob,
None;

T. J. Vyse,
None;

T. B. Niewold,
None;

P. M. Gaffney,
None;

J. A. James,
None;

R. P. Kimberly,
None;

G. S. Gilkeson,
None;

D. L. Kamen,
None;

C. D. Langefeld,
None;

D. M. Chang,
None;

Y. W. Song,
None;

W. Chen,
None;

J. M. Grossman,
None;

B. H. Hahn,
None;

B. P. Tsao,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/preferential-binding-to-elk-1-by-sle-associated-il10-risk-allele-up-regulates-il10-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology